Company Announcement no. 21/2013
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 13 November 2013
Veloxis Pharmaceuticals A/S establishes a new Warrant Programme
Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for a new employee of the company. Thus, the Board of Directors of the Company has today partly exercised its authorisation pursuant to Section 5A of the Articles of Association.
A total of 50,000 warrants are to be awarded, giving the right to subscription of up to 50,000 shares each of DKK 0.1. The exercise price is fixed at DKK 0.63.
The warrant holders earn the right to exercise warrants with 1/36 per month as from the date of grant 13 November 2013. Warrants that are not exercised on 13 November 2020 expire automatically.
The issued warrants are estimated to have a total market value of DKK 13,012. The market value of the issued warrants is calculated on basis of the Black-Scholes model with a volatility calculated as 52%, an interest level of 0.44%, and a share price of DKK 0.63.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: wjp@veloxis.com Email: jst@veloxis.com
For further information, please visit www.veloxis.com.
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
